Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma.
Adithya BalasubramanianAshray GunjurUmbreen HafeezSiddharth MenonLawrence M CherSagun ParakhHui Kong GanPublished in: Neuro-oncology advances (2020)
Our findings highlight the critical role of optimally designed phase II trials in informing drug development for GBM.